
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology is a late-stage clinical biopharmaceutical company with a promising product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company has a strong pipeline and upcoming catalysts, including a potential BLA filing in 2026 and data updates for multiple clinical trials. While the financials show increasing spend, the company has a strong cash position to support its operations through 2029. Risks to achieving their price target include potential clinical failures and challenges in gaining regulatory approval and commercializing their products, but their early data has shown compelling activity and a clean safety profile.
Bears say
CG Oncology is a late-stage biopharmaceutical company with a negative outlook due to the competitive landscape and potential limitations in their product candidate. Despite potential catalysts such as upcoming Phase 3 data and BLA filing, the company faces challenges in differentiating itself in the market and addressing questions around durability, schedule preference, and competitive positioning. The ongoing global BCG shortage may provide some opportunities, but the company's potential peak revenues of $3B in 2034 are lower compared to other competitors in the same space.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares